Company intelligence / Profile preview

Ex Oculis

Lausanne, Switzerlandpoetryfoundation.org ↗

Ownership: Public · OCULIS
Development stage: Other

Overview

Oculis has three core clinical assets. OCS‑01 completed enrollment of over 800 patients in two Phase 3 trials for DME with topline data expected Q2 2026. Licaminlimab (OCS‑02) will enter registrational trials for DED using a genotype-based approach. Privosegtor (OCS‑05) showed positive neuroprotective effects in the ACUITY trial for AON and may expand to broader neurophthalmic indications. The company maintains a strong cash position and expects several near-term value inflection points.

Therapeutic areas: OphthalmologyNeurology
Modalities: Small moleculeBiologicProtein
Industry: Biotech

Beyond the preview

Go deeper on Ex Oculis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ex Oculis.

Explore the full profile